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Article points
1. As part of service evaluation, 
a focus group was held to 
identify improvements for those 
with type 2 diabetes in the 
transition to injectable therapy.
2. The themes that arose were: 
the emotional response, 
communication, knowledge 
provision and support from 
healthcare providers.
3. It is recommended that shared 
decision making is promoted 
in order to improve the 
experience of transition.
4. A pre-injection education 
programme is planned 
in an attempt to reduce 
the psychological stress 
associated with the transition 
to injectable therapy. 
5. This area will continue to be an 
important issue for the health 
service in light of the increasing 
number of people being 
diagnosed with type 2 diabetes.
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The transition from oral to injectable agents is often delayed in type 2 diabetes 
by both people with diabetes and their healthcare providers. This study aimed 
to assess the experiences of people with type 2 diabetes in order to identify 
improvements that could be made in the transition to injectable therapy. Both 
positive and negative experiences were identified and a number of practice 
recommendations have been made, which may improve the experience of 
transition for all individuals. This will continue to be an important issue for the 
health service due to the increasing number of people being diagnosed with 
type 2 diabetes and the emphasis on “treating to target”.
Type 2 diabetes is often initially treated with lifestyle intervention, followed by the sequential introduction of oral 
hypoglycaemic agents. However, because of 
the progressive nature of the condition and 
the need to attain glycaemic targets, it may be 
necessary to initiate injection therapy in the 
form of either insulin or a glucagon-like peptide 
(GLP-1) analogue in a significant proportion of 
individuals (Abdul-Ghani et al, 2013). 
This transition from oral to injectable agents 
is often delayed by both people with diabetes 
and their clinicians (Siminerio, 2006; Peyrot 
et al, 2010). In one UK study, it took 1.8 years 
before 25% of people in whom oral therapy had 
failed were started on insulin. It was a further 
5 years before 50% of individuals were taking 
insulin, even in the presence of diabetes-related 
complications (Rubino et al, 2007). This 
delay exposes the individual to prolonged 
periods of hyperglycaemia and increased risk 
of complications (UKPDS [UK Prospective 
Diabetes Study] Group, 1998). It can also result 
in the individual becoming frustrated with 
their efforts to control their diabetes, leading 
to reduced motivation, less active self-care and 
treatment pessimism (Peyrot et al, 2010). 
This “clinical inertia” or reluctance to 
start insulin therapy is often known as 
psychological insulin resistance (Peyrot et al, 
2010). Its contributing factors are diverse and 
multi-factorial, including practical, psychosocial 
and behavioural issues (Bogatean and Hâncu, 
2004). These include an unwillingness to 
accept the need for such a step-up in treatment, 
fear of injecting, the perceived complexity of 
treatment and the potential for side-effects and 
complications. 
Insulin use is also associated with a social 
stigma and a sense of failure in terms of self-
management (Bogatean and Hâncu, 2004; Brod 
et al, 2009; Peyrot et al, 2010). As a result, the 
initiation of injectable therapy can be one of 
the most diff icult and important choices that 
individuals with diabetes have to make (Brod et 
al, 2009). 
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Aim
The current study aimed to assess the experiences of people 
with type 2 diabetes in order to identify improvements that 
could be made in the transition to injectable therapy.
Method
This work was undertaken at the diabetes service at 
Altnaglevin Hospital (Western Health and Social Care Trust). 
The hospital diabetes clinic serves a catchment population 
of around 120 000 and comprises a multidisciplinary team 
(dietitians, doctors, nurses, podiatrists and psychologists). The 
majority of people participated in shared-care arrangements 
with hospital and primary-care-based teams. As this work arose 
from a local service evaluation, ethics committee approval 
was not required. However, all participation was voluntary. 
Confidentiality and anonymity were observed during all 
phases of data collection and reporting. 
A focus group approach, where information is generated 
through group discussions (Morgan, 1998), was adopted. 
This provides the opportunity for participants to ref lect on 
and react to the opinions of others. It also has the potential 
to identify a wide range of opinions, as well as underlying 
conf licts, which would have otherwise remained unknown 
(Parahoo, 2006). 
Adults with type 2 diabetes who had been commenced on 
an injectable agent (insulin or a GLP-1 analogue) within 
the previous year were identified from the hospital diabetes 
database. All had been individually initiated on their injectable 
therapy, rather than in a group setting. Out of the 91 potential 
participants identified, 22 had commenced insulin therapy and 
69 an injectable GLP-1 analogue. To allow for an anticipated 
non-response rate of 30%, 18 individuals were invited to 
participate and were selected using a purposive sampling 
process (Polit and Beck, 2010) based on age, gender and type 
of injectable therapy. All participants attended the same focus 
Box 1. Open and closed questions used in the interviews.
l	How did you feel when you were told you needed an injectable 
treatment?
l	What process did you go through at the diabetes clinic?
l	Do you feel you received enough nursing support?
l	Do you feel you received enough dietetic support?
l	Did your diet and lifestyle change?
l	How do you feel about injecting?
l	Do you have any concerns about future changes in treatment?
l	Would you have liked more education and support?
l	How would you like information delivered to you?
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group regardless of the type of injectable therapy 
or the length of time since transition.
The interview schedule included both open 
and closed questions (Box 1, previous page) 
and probes were used to encourage responses 
(Bowling, 2009). The focus group discussion 
was recorded digitally, with permission, and field 
notes were taken by the moderator (DMcC). 
The interview was then transcribed verbatim 
and analysed using thematic content analysis 
(Krueger and Casey, 2009). Initially, DMcC read 
the transcript a number of times to familiarise 
herself with the data. Interpretive comments and 
likely themes were then noted on the transcript 
and this information was brought together, along 
with key statements, to describe the themes. An 
independent analysis of the data was conducted 
by JG who reviewed and verified the results and 
major themes. 
Results
Twelve individuals participated in the focus 
group (Table 1), which lasted 1½ hours. A 
number of themes arose around their experiences 
of commencing injectable therapy and how it 
could be improved. These themes were: the 
emotional response, communication, knowledge 
provision and support from healthcare providers. 
The emotional response 
Many participants described feeling shocked 
when they were told they would have to start 
an injectable therapy. While some were unaware 
that injectable therapy was even a treatment 
option in type 2 diabetes, others had not realised 
that the step-up in treatment was so imminent.  
“It was a shock. Because I thought I was doing 
great because I had lost 2 stone last year.”
“Starting insulin was a shock….I thought I had 
more time.”
Many participants described feelings of fear 
and anxiety on commencing injectable therapy. 
This related to the practical aspects of diabetes 
management, such as self-injecting, avoiding 
hypoglycaemia, maintaining satisfactory 
glycaemia, but also the impact on their lifestyle, 
such as their ability to drive, go on holiday or 
socialise. 
“When I did go on it, I got very scared.”
“I would sit and worry about things.”
Many of these emotional responses resulted 
from perceived problems with communication 
and knowledge provision, which emerged as 
separate themes. 
Communication
A perceived failure to discuss the likely future 
need for injectable therapy, a lack of time to 
explain the need for the treatment change and an 
assumption that individuals would readily accept 
the step-up in treatment left some people feeling 
excluded from the decision-making process.
“The pancreas had failed so they decided then 
to put me on insulin, [they] just say you’re on 
it, have a word with the dietitian, have a word 
with the diabetic nurse.”
Injectable 
therapy
Individual Duration of type 2 
diabetes (years)
HbA1c 
(mmol/mol)
BMI (kg/m2) Gender
1 5.6 51.9 25.3 M
2 12.7 92.4 37.8 M
3 9.8 49.7 30.6 M
4 15.7 93.4 31.6 F
5 13.5 68.3 44.0 F
6 9 59.6 30.1 F
7 18.1 61.7 32.0 M
8 19.5 76.0 27.6 M
9 17 86.9 M
10 16.8 81.4 31.6 F
11 15.6 62.8 51.3 F
12 19.7 55.2 42.2 F
Mean 14.4 69.9 (8.6%) 34.9
Table 1. Sample demographics.
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Participants felt that “some preparation 
time would be good” so that they could feel 
they were “edging towards” injectable therapy. 
Indeed, when they had been warned and the 
rationale explained, individuals were much 
more accepting of the change in treatment.
“I had been told it might be a possibility and 
why, and I’ d been told each time I came to the 
clinic. I think I didn’t panic because I had been 
told more gradually.”
Knowledge provision
When initially started on injectable therapy, a 
lack of clear and concise information could lead 
to “information overload” for some participants: 
“Many people are telling you many different 
things [and] it’s very difficult to take it all in.” 
Gaps in knowledge, particularly surrounding 
blood glucose monitoring and diet, made 
diabetes self-management diff icult. 
“Well, when I was 15 to 17 [mmol/L], that 
would alarm me, they said it was high, but 
some people tell me 4 [mmol/L] is high.”
“It wasn’t until lately that I found out that, 
that the more starchy or stodgy breads, the 
worse they were for me.”
It was suggested that providing more 
information before the change to an injectable 
therapy would have meant that individuals 
“might not have worried so much” and 
“could’ve been doing things right from the 
start”. Written information was seen as helpful: 
“It’s good to have the leaf lets to back up what 
they tell you in clinic, sometimes you don’t take 
it all in at the time.”
Support from health care providers 
The majority of participants talked positively 
about the clinical care and support they 
received from healthcare professionals, 
particularly the diabetes specialist nurses. If 
they encountered problems with their injectable 
therapy, it was easy to get advice over the 
telephone or to have an urgent appointment 
scheduled:
“I would have no problem lifting the phone 
talking to [a nurse] and saying ‘I’m … this is 
my situation, what can you do?’”
“There were days I’ d come up and say I don’t 
feel at all well, hitting high spots and I was 
more or less taken straight into a consultant.”
Participants also felt supported in their 
decision making:
 “I was handed [an injectable agent]… couldn’t 
cope with that at all and felt confident enough 
that I could stop it knowing that no one was 
going to have a go at me.”
However, there were occasions when 
individuals felt that they had received 
conf licting messages and this resulted in 
unnecessary anxiety:
“I wasn’t too happy with them at all, it was 
like, ‘you’re very close to insulin’, so I got myself 
mentally prepared on the next visit to ‘I’m going 
to get insulin this time’… So I went into the 
doctor and the doctor says no your bloods are 
perfect, your kidneys is working well, this is 
working but I’m prepared now, and it didn’t 
happen.” 
This may have arisen due to a changed clinical 
situation. It is important that there is effective 
communication between the patient and all 
members of the clinical team so that the patient 
understands the time-line leading to injectable 
therapy and the factors that will determine when 
exactly the change might occur.  
Discussion 
Consistent with previous work (Bogatean and 
Hâncu, 2004; Noh et al, 2005; Peyrot et al, 
2005; Wood, 2005) the majority of participants 
in this study described a negative emotional 
response when they were informed that they 
would need to commence an injectable therapy. 
In particular, a perceived lack of effective 
Page points
1. It is important that there is 
effective communication 
between the patient and 
all members of the clinical 
team so that the patient 
understands the time-line 
leading to injectable therapy.
2. The majority of participants in 
this study described a negative 
emotional response when 
they were informed that they 
would need to commence 
an injectable therapy.
Understanding barriers to commencing injectable therapy in people with type 2 diabetes
Journal of Diabetes Nursing Volume 19 No 6 2015 219
communication and knowledge provision 
ahead of the transition to injectable therapy left 
individuals feeling shocked, fearful and anxious. 
Care guidelines have consistently advocated 
that those with type 2 diabetes are informed 
from the time of diagnosis that it is a progressive 
condition that will often require insulin therapy 
(NICE, 2009). Although guidelines are in place, 
it is unclear to what extent these are adhered 
to, or to what extent individuals with diabetes 
fully understand the progressive nature of 
their condition and the possibility of requiring 
injectable therapy. Communication research has 
shown that dissonance between what healthcare 
professionals think they have covered with 
patients, compared with patients’ perceptions 
of a consultation is not uncommon (Parkin and 
Skinner, 2003). Communication needs to be 
improved to minimise these discrepancies. 
Current healthcare policy in Northern Ireland 
(Department of Health, Social Services and 
Public Safety, 2011) and elsewhere reinforces the 
need for empowered people who can self-manage 
long-term conditions, yet the impression from 
these results, for some people at least, was one of 
relative disempowerment: 
“... so they decided then to put me on insulin, 
just say ‘you’re on it, have a word with the 
dietitian …’” 
A systematic review of the literature relating 
to communication between healthcare 
professionals and patients regarding medicines 
reported that: 
“Patients rarely initiate medication topics 
and can take a passive role when discussing 
medicines with health care practitioners.” 
(Stevenson et al, 2004). 
It is essential to advance practice and encourage 
empowered and knowledgeable individuals to 
take an active part in discussions about their 
treatment progression. The benefits of a more 
pro-active patient approach include greater 
patient engagement and satisfaction (Stevenson 
et al, 2004).
People with diabetes may interact over time 
with different members of the diabetes team 
in both a hospital and community setting. 
Although it is important that a consistent 
message is given by different team members, 
this can be difficult to maintain over the longer 
term, particularly as the individual’s clinical 
situation, and as a result their care plan, may 
change rapidly (Haggerty et al, 2003).
In order to help overcome potential 
barriers to starting injectable therapy, 
appropriate education to increase knowledge, 
promote shared decision making and reduce 
psychological stress is required. While there 
are education programmes available for the 
introduction of insulin and GLP-1 analogues, 
such as X-PERT Insulin (©X-PERT Health) 
and the Injectable Therapies Toolkit (©The 
DESMOND Collaborative), these relate 
largely to the administration of therapy and 
the management of the condition through 
injections. They do not prepare people for the 
eventual transition from oral agents to injectable 
therapy.
The findings of this study suggest that some 
of the anxiety and stress associated with a 
decision to move to injectable therapy might 
be mitigated by a specific “pre-injectable” 
education programme delivered some time 
before it becomes necessary. This programme 
might address the rationale for injectable 
therapy, what factors might indicate the need 
for a move to injectable therapy, an overview 
of how such treatments might be delivered and 
individualised, and to address patient concerns 
and fears. While the rate of progression of 
type 2 diabetes will vary between individuals, 
such an education programme might be offered 
when people move to three separate oral anti-
diabetic agents, or when there is an expectation 
by the clinical team that injectable therapy will 
be required within 12 months. It is recognised 
that there will always be some individuals 
where the decision to move to an injectable 
agent, particularly insulin, will have to be 
taken immediately with often little time for 
preparation.
The recommendations arising from this study 
are:
l Review how information about treatment 
progression is delivered, including an 
Page points
1. It is essential to advance 
practice and encourage 
empowered and knowledgeable 
individuals to take an active 
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their treatment progression.
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potential barriers to starting 
injectable therapy, appropriate 
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assessment of the extent to which this 
information has been understood. 
l Develop a specific “pre-injectable” education 
programme to be offered to individuals where 
it is considered that injectable therapy will be 
needed within 12 months. 
A weakness of the current study was that the 
patient group was self selected and therefore the 
experiences described may not be representative 
of the entire diabetes population starting 
injectable therapy. Furthermore, the number 
of participants was small and limited to one 
service.
Conclusion
The present study found that a majority of 
participants had a negative emotional reaction 
to the decision to start injectable therapy. It is 
proposed that an educational programme be 
developed to prepare people for progression to 
injectable therapy, enhance participation in 
decision making and to minimise any adverse 
emotional impact. This might help overcome 
clinician and patient barriers to commencing 
injectable therapy, and result in an improved 
experience for people with diabetes and better 
glycaemic control.  n
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“The findings of this 
study suggest that 
some of the anxiety 
and stress associated 
with a decision to move 
to injectable therapy 
might be mitigated by a 
specific ‘pre-injectable’ 
education programme.”
